Rockefeller Capital Management L.P. Sells 26,197 Shares of Johnson & Johnson (NYSE:JNJ)

Rockefeller Capital Management L.P. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 663,053 shares of the company's stock after selling 26,197 shares during the period. Rockefeller Capital Management L.P.'s holdings in Johnson & Johnson were worth $95,939,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. IFS Advisors LLC lifted its position in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after buying an additional 100 shares during the last quarter. WealthTrak Capital Management LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $26,000. Mountain Hill Investment Partners Corp. bought a new position in Johnson & Johnson during the fourth quarter worth about $29,000. Bay Harbor Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $32,000. Finally, Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $33,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.5 %

Shares of JNJ traded down $0.71 during trading hours on Tuesday, hitting $153.66. The company had a trading volume of 10,719,203 shares, compared to its average volume of 7,975,051. The firm has a market cap of $370.29 billion, a P/E ratio of 23.11, a P/E/G ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The stock's 50 day moving average price is $159.38 and its 200 day moving average price is $155.11. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Remove Ads

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.38%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is 74.59%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Barclays lifted their target price on Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a report on Tuesday, January 28th. Bank of America lowered their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Eight analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $171.50.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company's stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.